iBio, Inc Common Stock

Yahoo Finance • 8 days ago

Is it a Wise Move to Buy Liquidia Corp. (LQDA) Shares?

Arquitos Capital Management, an investment management firm, released its second-quarter 2025 investor letter. During the period, the fund delivered a net return of 13.1%, bringing year-to-date gains to an impressive 28.8% as of June 30, 20... Full story

Yahoo Finance • 26 days ago

iBio GAAP EPS of -$1.75, revenue of $0.4M beats by $0.2M

* iBio press release [https://seekingalpha.com/pr/20222653-ibio-reports-fiscal-year-2025-financial-results-and-provides-corporate-update] (NASDAQ:IBIO [https://seekingalpha.com/symbol/IBIO]): FY GAAP EPS of -$1.75. * Revenue of $0.4M (... Full story

Yahoo Finance • 27 days ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate updat... Full story

Yahoo Finance • last month

IBio Prices $50 Mln Public Offering To Advance Preclinical Antibody Programs

(RTTNews) - iBio, Inc. (IBIO), an AI-driven developer of precision antibody therapies, has priced an underwritten public offering of pre-funded warrants for 71.54 million shares and accompanying Series G and Series H warrants, raising appr... Full story

Yahoo Finance • last month

iBio Announces Pricing of $50 Million Public Offering

SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the “offering”) of (i) pre-funded warrants to... Full story

Yahoo Finance • last month

Curious about the stocks that are showing activity after the closing bell on Monday?

The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT LASE [https://www.chartmill.com/stock/q... Full story

Yahoo Finance • last month

iBio Announces Proposed Public Offering

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the “offering”) of (i) pre-funded warrants... Full story

Yahoo Finance • last month

Impact Biomedical announces 3F US patent issue

* Impact Biomedical (NYSE:IBO [https://seekingalpha.com/symbol/IBO]) announced on Monday that the US Patent and Trademark Office has issued a patent titled “Composition and Method of Controlling Infectious Diseases with Functional Fragra... Full story

Yahoo Finance • 3 months ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists... Full story

Yahoo Finance • 3 months ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO),... Full story

Yahoo Finance • 5 months ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting... Full story

Yahoo Finance • 6 months ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a first-in-class Activin E an... Full story

Yahoo Finance • 6 months ago

iBio, Inc. Common Stock (IBIO): Among Stocks Insiders Were Buying In Q1 2025

We recently published a list of 20 Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where iBio, Inc. Common Stock (NASDAQ:IBIO) stands against other stocks insiders were buying in Q1 2025. About 30 m... Full story